Open speed-vm opened 7 months ago
Should we include orals in this? There are already oral codelists for anticoagulants. If they are correct then if we made this just a parenterals list then researchers could use/combine both for comprehensive coverage?
Bemiparin not used in UK
AFAICT from the normalised_prescribing
table on BQ there were a handful in 2010 but nothing since
Yes good idea to do parenteral for future use
Need to just double check those non warfarin, vitamin K antagonists included though
From my work on codelist rot I'm leaning to prefer multiple, small codelists with clear purposes rather than large ones that serve multiple purposes
thanks @Jongmassey @speed-vm Have split oral/parenteral
https://www.opencodelists.org/codelist/user/matthewberesford92/oral-anticoagulation-used-for-treatment-of-vte-in-primary-care-uk-dmd-dmd/316ca70a/ https://www.opencodelists.org/codelist/user/matthewberesford92/anticoagulation-taken-for-vte-dmd/638b8d74/
Can you clarify why you excluded fonda 1.5mg (i am sure I have used this for prophylaxis ?)
Can you clarify why you excluded rivaroxaban 1.5mg
@matthewberesford92 Thank you Fonda 1.5 not included as trying to capture treatment doses rather than thromboprophylaxis. Riva 2.5 used for prophylaxis of atherothrombotic events. Dose would never be appropriate as a treatment for VTE.
@matthewberesford92 I have reviewed the Oral Anticoagulation codelist. I am happy with it, so please add my review to your codelist in the review section.
@matthewberesford92 Two comments for the parenteral anticoagulation codelist. 1) I think its catching, please can you change title to Parenteral rather than parental 2) Please remove this one Arixtra 1.5mg/0.3ml solution for injection pre-filled syringes (AMP) (13565111000001103)
Otherwise I am happy with that codelist. Thank you
You both are the clinical domain experts here but as far as I can see there's no obvious errors
@matthewberesford92 when you have time these codelists need my 'sign off' adding to the bottom, and then publishing (they still say under review)
https://www.opencodelists.org/codelist/user/matthewberesford92/oral-anticoagulation-used-for-treatment-of-vte-in-primary-care-uk-dmd-dmd/316ca70a/ https://www.opencodelists.org/codelist/user/matthewberesford92/anticoagulation-taken-for-vte-dmd/638b8d74/
sorry @speed-vm, didnt realise I hadnt published.Here they are.
For reference @acagreen17 @joshuamutio
https://www.opencodelists.org/codelist/user/matthewberesford92/anticoagulation-taken-for-vte/79218d24/ https://www.opencodelists.org/codelist/user/matthewberesford92/oral-anticoagulation-used-for-treatment-of-vte-in-primary-care-uk-dmd/4a7c1a3f/
User requirements
Codelist for anticoagulation that could be prescribed in primary care for the treatment and prevention of VTE. This will include oral and parenteral anticoagulants. This will be used together with VTE diagnosis codes to determine incident and prevalent VTE cases.
Sensitivity versus specificity
We will use medications most likely to be used for therapeutic anticoagulation for treatment and prevention of VTE. We will not extract medications that would only be used in a secondary care setting (eg. argatroban and unfractionated heparin)
Relevant definitions or links to important reference sources
No response
Coding system
dm+d
Existing relevant codelists
No response
Search terms / synonyms / search strategy
Anticoagulation and VTMs for codelist
Low molecular weight heparins 775768002 enoxaparin 775440000 dalteparin 777776004 tinzaparin Bemiparin not used in UK
Alternative to LMWH likely low usage 35312611000001107 Fondaparinux sodium (not 1.5mg)
Vitamin K antagonists 777947006 warfarin 774409003 acenocoumarol 777163004 phenindione
Direct oral anticoagulants 777455008 rivaroxaban (Not 2.5mg) 774624002 apixaban 775732007 edoxaban 13568411000001103 dabigatran
Inclusion criteria for codes
No response
Exclusion criteria for codes
2.5mg rivaroxaban 1.5mg fondaparinux
Borderline cases
Bemiparin not used in UK Unfractionated heparin not included as use is in secondary care
Final codelist
No response